News
Cancer Genetics Inc to Present New Data on Identification of Genomic Changes that Predict both Metastasis and Site of Metastasis in Kidney Cancer at the 2015 ASCO Genitourinary Cancers Symposium
By Italia on February 24 2015
CGI’s genomic signature, developed in a research collaboration with Memorial Sloan-Kettering, predicts metastasis for clear-cell renal cell carcinoma (ccRCC) Clear cell renal cell carcinoma is the most common form of kidney cancer with nearly 43,000 new cases in the US each year and 200,000 globally per year RUTHERFORD, NJ, February 24, 2015 (Globe Newswire) – […]
Continue ReadingCancer Genetics’ Unique, Next Generation Sequencing Panel for Chronic Lymphocytic Leukemia (CLL) Selected for Use in Global Clinical Trial by Leading Biotechnology Company
By Italia on February 17 2015
CGI’s unique next generation sequencing (NGS) panel, Focus::CLLTM, will be used to assess genetic aberrations and mutations that are clinically relevant and validated for CLL, the most common form of leukemia in the Western hemisphere. CLL accounts for one-third of all leukemias and the Focus::CLLTM panel helps in determining patient outcome and treatment selection. RUTHERFORD, N.J. […]
Continue ReadingCancer Genetics, Inc. to Participate in the BTIG Second Annual Snowbird Medical Technology, Diagnostics & Healthcare IT Conference
By Italia on February 12 2015
RUTHERFORD, N.J., Feb. 12, 2015 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “the Company”), an emerging leader in DNA-based cancer diagnostics, announced today that CEO and President Panna Sharma will participate in the BTIG Second Annual Snowbird Medical Technology, Diagnostics, and Healthcare IT Conference from February 18th to 20th. The conference, which is held at […]
Continue ReadingCancer Genetics Appoints Randy Goodman, Ph.D., as Director of Reimbursement and Clinical Revenue Cycle Management
By Italia on February 11 2015
RUTHERFORD, NJ, February 11, 2015 (Globe Newswire) – Cancer Genetics, Inc. (Nasdaq: CGIX; “CGI” or “the Company”), an emerging leader in DNA-based cancer diagnostics, announced today the appointment of Randy Goodman, Ph.D., as Director of Reimbursement and Clinical Revenue Cycle Management. Goodman is a nationally recognized expert in value-based reimbursement and brings more than 20 […]
Continue ReadingCancer Genetics, Inc. Launches Digital Platform to Enable Collaboration with Community Hospitals and Laboratories
By Italia on January 20 2015
RUTHERFORD, N.J., January 20, 2014 (GlobeNewswire) — Cancer Genetics, Inc., (Nasdaq: CGIX) (“CGI” or “the company”), an emerging leader in DNA-based cancer diagnostics, announced today the launch of their ExpandDxTM collaborative testing program. CGI’s ExpandDx program, which utilizes VENTANA digital pathology technology from Roche, allows community-based hospitals and pathology labs to partner with CGI through remote consultations, […]
Continue ReadingCancer Genetics, Inc. Receives Approval to Provide Oncology Testing for Patients in California
By Italia on January 5 2015
>> Approval Allows CGI to Access Largest National Market for Oncology Testing Services RUTHERFORD, N.J., January 05, 2015 (Globe Newswire) —Cancer Genetics, Inc. (Nasdaq: CGIX, “CGI” or “the company”), an emerging leader in DNA-based cancer diagnostics, announced today that its CLIA-certified, CAP-accredited reference laboratory has received licensure from the California Department of Health. The California Clinical Laboratory License […]
Continue ReadingCancer Genetics, Inc. to Present at 26th Annual Piper Jaffray Healthcare Conference
By Italia on December 1 2014
RUTHERFORD, N.J., December 1, 2014 (Globe Newswire) — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “the Company”), an emerging leader in DNA-based cancer diagnostics, announced today that it will present at the 26th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December 2, 2014. Representatives from the company will speak at 8:10 am EST. A webcast of the presentation […]
Continue ReadingCancer Genetics Inc Recognized in Deloitte’s 2014 Technology Fast 500™ Awards
By Italia on November 14 2014
> CGI Recognized as One of North America’s Fastest Growing Companies Based on Revenue Growth. RUTHERFORD, N.J., November 14, 2014 (Globe Newsire) — Cancer Genetics, Inc. (Nasdaq: CGIX) (“CGI” or “the company”), an emerging leader in DNA-based cancer diagnostics, today announced it ranked 303 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing […]
Continue ReadingCancer Genetics Inc to Present at Cannacord Genuity Medical Technology & Diagnostics Conference
By Italia on November 13 2014
RUTHERFORD, N.J., November 13, 2014 (Globe Newswire) — Cancer Genetics, Inc., (Nasdaq: CGIX) an emerging leader in DNA-based cancer diagnostics, announced today that the company’s CEO, Panna Sharma, will present at the upcoming Canaccord Genuity Medical Technology & Diagnostics Conference. The event, which will be held at the Westin Grand Central in New York on Thursday, […]
Continue ReadingCancer Genetics Inc Receives Second Patent for Genomic Cervical Cancer Test; Strengthens Position of FHACT®
By Italia on November 11 2014
Company receives second patent (US Patent No. 8,883,414) for FHACT® FHACT® has potential to improve cervical cancer detection for up to 2 million women in the US each year. RUTHERFORD, N.J., November 11, 2014 — Cancer Genetics Inc, an emerging leader in DNA-based cancer diagnostics, announced today that it has received a second US patent […]
Continue Reading